Optho Pharma Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
as on 23-10-2024
- Paid Up Capital ₹ 4.14 M
as on 23-10-2024
- Company Age 6 Year, 2 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 1.11 Cr
as on 23-10-2024
- Revenue -4.37%
(FY 2023)
- Profit 76.85%
(FY 2023)
- Ebitda 46.11%
(FY 2023)
- Net Worth 62.42%
(FY 2023)
- Total Assets -2.73%
(FY 2023)
About Optho Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 4.14 M.
The company currently has active open charges totaling ₹1.11 Cr.
Rajesh Agarwal and Rohit Agarwal serve as directors at the Company.
- CIN/LLPIN
U33100UP2018PTC109224
- Company No.
109224
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
15 Oct 2018
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Kanpur
Industry
Company Details
- Location
Allahabad, Uttar Pradesh, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Optho Pharma Private Limited offer?
Optho Pharma Private Limited offers a wide range of products and services, including Cleaning Liquids & Wipes, Kitchen Cleaners, Common Disease Medicines, Eye Drops.
Who are the key members and board of directors at Optho Pharma?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rajesh Agarwal  | Director | 15-Oct-2018 | Current |
| Rohit Agarwal | Director | 15-Oct-2018 | Current |
Financial Performance of Optho Pharma.
Optho Pharma Private Limited, for the financial year ended 2023, experienced Minor drop in revenue, with a 4.37% decrease. The company also saw a substantial improvement in profitability, with a 76.85% increase in profit. The company's net worth Soared by an impressive increase of 62.42%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Optho Pharma?
In 2022, Optho Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
State Bank Of India Creation Date: 14 Oct 2019 | ₹1.11 Cr | Open |
How Many Employees Work at Optho Pharma?
Optho Pharma has a workforce of 22 employees as of Apr 05, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Optho Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Optho Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
